Catalytic activities and substrate specificity of the human membrane type 4 matrix metalloproteinase catalytic domain

被引:60
作者
Wang, YH [1 ]
Johnson, AR [1 ]
Ye, QZ [1 ]
Dyer, RD [1 ]
机构
[1] Warner Lambert Co, Parke Davis Pharmaceut Res Div, Dept Biochem, Ann Arbor, MI 48105 USA
关键词
D O I
10.1074/jbc.274.46.33043
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Membrane type (MT) matrix metalloproteinases (MMPs) are recently recognized members of the family of Zn2+- and Ca2+-dependent MMPs. To investigate the proteolytic capabilities of human MT4-MMP (i.e. MMP-17), we have cloned DNA encoding its catalytic domain (CD) from a breast carcinoma cDNA library. Human membrane type 4 MMP CD (MT4-MMPCD) protein, expressed as inclusion bodies in Escherichia coli, was purified to homogeneity and refolded in the presence of Zn2+ and Ca2+. While MT4-MMPCD cleaved synthetic MMP substrates Ac-PLG-[2-mercapto-4-methylpentanoyl]-LG-OEt and Mca-PLGL-Dpa-AR-NH2 with modest efficiency, it catalyzed with much higher efficiency the hydrolysis of a pro-tumor necrosis factor-ct converting enzyme synthetic substrate; Mca-PLAQAV-DpaR-SSSR-NH2. Catalytic efficiency with the pro-tumor necrosis factor-a: converting enzyme substrate was maximal at pH 7.4 and was modulated by three ionizable enzyme groups (pK(a3) = 6.2, pK(a2) = 8.3, and pK(a1) = 10.6). MT4-MMPCD cleaved gelatin but was inactive toward type I collagen, type IV collagen, fibronectin, and laminin. Like all known MT-MMPs, MT4-MMPCD was also able to activate 72-kDa progelatinase A to its 68-kDa form. EDTA, 1,10-phenanthroline, reference hydroxamic acid MMP inhibitors, tissue inhibitor of metalloproteinases-l, and tissue inhibitor of metalloproteinases-a all potently blocked MT4-MMPCD enzymatic activity. MT4-MMP is, therefore, a competent Zn2+-dependent MMP with unique specificity among synthetic substrates and the capability to both degrade gelatin and activate progelatinase A.
引用
收藏
页码:33043 / 33049
页数:7
相关论文
共 39 条
[1]   STROMELYSIN-1 - 3-DIMENSIONAL STRUCTURE OF THE INHIBITED CATALYTIC DOMAIN AND OF THE C-TRUNCATED PROENZYME [J].
BECKER, JW ;
MARCY, AI ;
ROKOSZ, LL ;
AXEL, MG ;
BURBAUM, JJ ;
FITZGERALD, PMD ;
CAMERON, PM ;
ESSER, CK ;
HAGMANN, WK ;
HERMES, JD ;
SPRINGER, JP .
PROTEIN SCIENCE, 1995, 4 (10) :1966-1976
[2]   THE C-TERMINAL REGION OF MEMBRANE TYPE MATRIX METALLOPROTEINASE IS A FUNCTIONAL TRANSMEMBRANE DOMAIN REQUIRED FOR PRO-GELATINASE-C ACTIVATION [J].
CAO, J ;
SATO, H ;
TAKINO, T ;
SEIKI, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (02) :801-805
[3]   PROTEOGLYCAN DEGRADATION BY A CHONDROCYTE METALLOPROTEASE - EFFECTS OF SYNTHETIC PROTEASE INHIBITORS [J].
CAPUTO, CB ;
WOLANIN, DJ ;
ROBERTS, RA ;
SYGOWSKI, LA ;
PATTON, SP ;
CACCESE, RG ;
SHAW, A ;
DIPASQUALE, G .
BIOCHEMICAL PHARMACOLOGY, 1987, 36 (07) :995-1002
[4]   Matrix metalloproteinases and the development of cancer [J].
Coussens, LM ;
Werb, Z .
CHEMISTRY & BIOLOGY, 1996, 3 (11) :895-904
[5]   X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily [J].
Dhanaraj, V ;
Ye, QZ ;
Johnson, LL ;
Hupe, DJ ;
Ortwine, DF ;
Dubar, JB ;
Rubin, JR ;
Pavlovsky, A ;
Humblet, C ;
Blundell, TL .
STRUCTURE, 1996, 4 (04) :375-386
[6]   MATRIX METALLOPROTEINASES AND CARDIOVASCULAR-DISEASE [J].
DOLLERY, CM ;
MCEWAN, JR ;
HENNEY, AM .
CIRCULATION RESEARCH, 1995, 77 (05) :863-868
[7]  
ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405
[8]  
Galardy Richard E., 1993, Drugs of the Future, V18, P1109
[9]   Overview of matrix metalloproteinase expression in cultured human cells [J].
Giambernardi, TA ;
Grant, GM ;
Taylor, GP ;
Hay, RJ ;
Maher, VM ;
McCormick, JJ ;
Klebe, RJ .
MATRIX BIOLOGY, 1998, 16 (08) :483-496
[10]   Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1 [J].
GomisRuth, FX ;
Maskos, K ;
Betz, M ;
Bergner, A ;
Huber, R ;
Suzuki, K ;
Yoshida, N ;
Nagase, H ;
Brew, K ;
Bourenkov, GP ;
Bartunik, H ;
Bode, W .
NATURE, 1997, 389 (6646) :77-81